Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
14.54
+0.18 (1.25%)
At close: Mar 28, 2025, 4:00 PM
14.53
-0.01 (-0.05%)
After-hours: Mar 28, 2025, 7:56 PM EDT

Company Description

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases.

The company’s lead product candidate is Descartes-08, an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA) for the treatment of autoimmune diseases, currently under Phase 2b clinical development for generalized myasthenia gravis, systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis.

It develops Descartes-15, an autologous anti-BCMA mRNA CAR-T to treat autoimmune diseases such as relapsed/refractory multiple myeloma.

Cartesian Therapeutics, Inc. is headquartered in Frederick, Maryland.

Cartesian Therapeutics, Inc.
Cartesian Therapeutics logo
Country United States
Founded 2007
IPO Date Jun 22, 2016
Industry Biotechnology
Sector Healthcare
Employees 66
CEO Carsten Brunn

Contact Details

Address:
7495 New Horizon Way
Frederick, Maryland 21703
United States
Phone 301 348 8698
Website cartesiantherapeutics.com

Stock Details

Ticker Symbol RNAC
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001453687
CUSIP Number 816212302
ISIN Number US8162123025
SIC Code 2834

Key Executives

Name Position
Dr. Carsten Brunn Ph.D. President, Chief Executive Officer and Director
Blaine T. Davis Chief Financial Officer
Dr. Metin Kurtoglu M.D., Ph.D. Chief Technology Officer
Dr. Chris Jewell Ph.D. Chief Scientific Officer
Matthew Bartholomae J.D. General Counsel and Secretary
Dr. Milos Miljkovic M.D., Ph.D. Chief Medical Officer
Dr. Emily English Ph.D. SVice President and Head of Manufacturing

Latest SEC Filings

Date Type Title
Mar 13, 2025 10-K Annual Report
Mar 13, 2025 8-K Current Report
Mar 3, 2025 8-K Current Report
Feb 12, 2025 SCHEDULE 13G/A Filing
Jan 27, 2025 8-K Current Report
Jan 15, 2025 SCHEDULE 13D/A Filing
Jan 13, 2025 EFFECT Notice of Effectiveness
Jan 13, 2025 EFFECT Notice of Effectiveness
Jan 13, 2025 8-K Current Report
Jan 10, 2025 POS AM Post-Effective amendments for registration statement